,,iii #aag? ,,congress #a/ ,session ,s4 ,,res4 #gd ,,9 ,,! ,,s5ate ,,( ,,! ,,unit$ ,,/ates ,febru>y #bd1 #bjba,mr4 ,br[n 7= himself1 ,mr4 ,b>rasso1 ,mr4 ,blum5?al1 ,mr4 ,scott ( ,s\? ,c>ol9a1 ,ms4 ,klobu*>1 ,mr4 ,wick]1 ,mr4 ,m>key1 & ,mr4 ,book]7 submitt$ ! foll[+ resolution2 :i* 0 consid]$ & agre$ to ,,resolution ,designat+ ,febru>y #bh1 #bjba1 z ,r>e ,disease ,day4 ,:]eas a r>e disease or disord] is a disease or disord] t affects a small numb] ( pati5ts2 ,:]eas1 9 ! ,unit$ ,/ates1 a r>e disease or disord] typically affects few] ?an #bjj1jjj individuals2 ,:]eas1 z ( ! date ( ! adoption ( ?is resolution1 m ?an #g1jjj r>e diseases or disord]s affect approximately #a 9 #aj individuals 9 ! ,unit$ ,/ates2 ,:]eas *ildr5 ) r>e diseases or disord]s acc\nt = a significant portion ( ! population affect$ by r>e diseases or disord]s 9 ! ,unit$ ,/ates2 ,:]eas _m r>e diseases & disord]s are s]i\s & life-?reat5+ & lack effective treatm5ts2 ,:]eas1 z a result ( ! enactm5t ( ! ,orphan ,drug ,act 7,public ,law #ig-dad2 #if ,/at4 #bjdi71 important advances h be5 made 9 ! rese>* & treatm5t ( r>e diseases & disord]s2 ,:]eas ! ,food & ,drug ,adm9i/ration has made /rides 9 ga!r+ pati5t p]spectives to in=m ! drug review process z "p ( ! ,pati5t-,focus$ ,drug ,developm5t program1 an initiative t 0 reaffirm$ "u ! ,,fda ,reau?orization ,act ( #bjag 7,public ,law #aae-eb2 #aca ,/at4 #ajje72 ,:]eas1 al?\gh ! ,food & ,drug ,adm9i/ration has approv$ m ?an #hhj orphan indications = drugs & biological products = ! treatm5t ( r>e diseases & disord]s1 #ij p]c5t ( individuals 9 ! ,unit$ ,/ates ) a r>e disease or disord] are n receiv+ an ,,fda-approv$ treatm5t = _! condition2 ,:]eas limit$ treatm5t options & difficulty obta9+ reimbursem5t = life-alt]+ & lifesav+ treatm5ts c be *all5g+ = individuals ) r>e diseases or disord]s & _! families2 ,:]eas r>e diseases & disord]s include sickle cell anemia1 sp9al muscul> atrophy1 common v>iable immune defici5cy1 m$ian arcuate ligam5t syndrome1 glycog5 /orage disease type ,v1 pulmon>y hyp]t5sion1 hemophilia1 cy/ic fibrosis1 s>coidosis1 amyotrophic lat]al scl]osis1 & autosomal recessive polycy/ic kidney disease2 ,:]eas individuals ) r>e diseases or disord]s c exp]i5ce difficulty 9 obta9+ accurate diagnoses & f9d+ physicians or treatm5t c5t]s ) exp]tise 9 _! r>e disease or disord]2 ,:]eas ! #aaf? ,congress pass$ a #d-ye> ext5sion ( ! ,r>e ,p$iatric ,disease ,priority ,review ,v\*] program "u section #ebi7;b7 ( ! ,f$]al ,food1 ,drug1 & ,cosmetic ,act 7#ba ,u4,s4,c4 #cfj;ff7b77 z "p ( ! ,consolidat$ ,appropriations ,act1 #bjba 7,public ,law #aaf-bfj2 #acd ,/at4 #aahb71 provid+ an inc5tive = ! developm5t ( !rapies = *ildr5 ) r>e diseases2 ,:]eas ! #aaf? ,congress pass$ ! ,advanc+ ,c>e = ,exceptional ,kids ,act 7,public ,law #aaf-af2 #acc ,/at4 #heb71 improv+ access to coord9at$1 pati5t-c5t]$ heal? c>e = *ildr5 ) complex & r>e m$ical conditions 9 ,m$icaid2 ,:]eas ! ,food & ,drug ,adm9i/ration & ! ,national ,in/itutes ( ,heal? support rese>* on ! treatm5t ( r>e diseases & disord]s2 ,:]eas #bjba m>ks ! #ch? anniv]s>y ( ! enactm5t ( ! ,orphan ,drug ,act 7,public ,law #ig-dad2 #if ,/at4 #bjdi72 ,:]eas ,r>e ,disease ,day is obs]v$ ea* ye> on ! la/ day ( ,febru>y2 ,:]eas ,r>e ,disease ,day is a global ev5t t 0 fir/ obs]v$ 9 ! ,unit$ ,/ates on ,febru>y #bh1 #bjji1 & 0 obs]v$ 9 m ?an #ajj c\ntries 9 #bjbj2 & ,:]eas ,r>e ,disease ,day is expect$ to be obs]v$ globally = ye>s to come1 provid+ hope & in=mation = r>e disease & disord] pati5ts ar\nd ! _w3 ,n[1 !re=e1 be x ,t ! ,s5ate-- 7#a7 designates ,febru>y #bh1 #bjba1 z ,r>e ,disease ,day2 & 7#b7 recognizes ! importance (1 ) respect to r>e diseases & disord]s-- 7,a7 improv+ aw>5ess2 7,b7 enc\rag+ accurate & e>ly diagnosis2 & 7,c7 support+ national & global ef=ts to develop effective treatm5ts1 diagno/ics1 & cures4